
We also calculated the reporting odds ratios (RORs) of suspected drugs (conventional DOX PEGylated-liposome DOX non-PEGylated-liposome DOX).

This study relied on definitions of preferred terms provided by the Medical Dictionary for Regulatory Activities (MedDRA) and the standardized MedDRA Queries (SMQ) database. The SRS used was the US Food and Drug Administration Adverse Event Reporting System (FAERS). This is the first study to evaluate the effect of a liposomal formulation of DOX using spontaneous reporting system (SRS) databases.

The aim of this study was to assess the adverse event profiles of conventional DOX and liposomal DOX. Doxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumors.
